- /
- Supported exchanges
- / KQ
- / 214450.KQ
Pharma Reaserch Prod Co Ltd (214450 KQ) stock market data APIs
Pharma Reaserch Prod Co Ltd Financial Data Overview
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pharma Reaserch Prod Co Ltd (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pharma Reaserch Prod Co Ltd data using free add-ons & libraries
Get Pharma Reaserch Prod Co Ltd Fundamental Data
Pharma Reaserch Prod Co Ltd Fundamental data includes:
- Net Revenue: 496 027 M
- EBITDA: 211 900 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-19
- EPS/Forecast: 3686.32
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharma Reaserch Prod Co Ltd News
New
REJURAN COSMETICS Debuts at Sephora, Expanding Its Footprint Across the U.S. Market
Korea No.1 medical aesthetic brand launches online and in 380 Sephora offline stores LOS ANGELES, March 12, 2026 /PRNewswire/ -- REJURAN COSMETICS, No.1 medical aesthetic brand developed by global ph...
K-pop Singer and Actress Kim Sejeong Named Global Brand Ambassador for 'REJURAN' and 'REJURAN COSMETICS'
GANGNEUNG, South Korea, March 10, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO Jihoon Sohn) announced that singer and actress Kim Sejeong has been named the new global brand ambassador for its f...
PharmaResearch Announces Supply Agreement for Rejuran in Brazil
SEONGNAM, South Korea, Feb. 11, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO Jihoon Sohn), a leading regenerative medicine company, announced that it has entered into an exclusive supply agreeme...
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Dru...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.